



# PEPFAR

U.S. President's Emergency Plan for AIDS Relief

# From 95-95-95 to zero new infections, zero deaths, reduced stigma

---

Ambassador Deborah Birx

IAS

July 2018

15 YEARS OF SAVING LIVES THROUGH AMERICAN GENEROSITY AND PARTNERSHIPS

#PEPFAR15

Moving from  
generic to specific  
Moving from words  
to action  
Holding ourselves  
accountable



# Where are we?

## Eastern and Southern Africa

Expansion of services through **deliberative collaboration** between PEPFAR, GF, governments, and community

**Demonstrated outcomes lead to impact; rapid policy adoption, continuous monitoring of progress**

GAPS : **Prevention** interventions to saturation  
15-30 age group

**Early Treatment** - Men – all ages


**Clinical and prevention cascade for key populations**

**PEPFAR**  
U.S. President's Emergency Plan for AIDS Relief




High  
prevalence  
generalized  
epidemics

# Ethiopia



## South Sudan



Lesson learned from East and Southern Africa – the progress to date – nearly a 50% decline in incidence has occurred with missing more than 50% of the men – especially healthy young men – if this is addressed the epidemic can be controlled

# Where are we?

## West/West Central Africa

Slow expansion of critical prevention and treatment services despite resources  
Unclear epidemiology with mixed epidemics

**Slow policy adoption, user fees – formal and informal- prevent access to health services; unrelenting stigma and discrimination;**

### Key gaps

Clinical and prevention cascade for key populations  
Inconsistent political will to address all key populations with necessary interventions  
Ensuring access to services for young people and men of all ages  
Strategies to address stigma and discrimination


**PEPFAR**

U.S. President's Emergency Plan for AIDS Relief



Low  
prevalence  
mixed  
epidemics

# Cameroon





Lesson learned from West  
and West Central Africa  
region:

**POLICIES Matter**

Progress in policy changes  
necessary for success  
otherwise progress will  
remain stalled

# Where are we?

## Key population epidemics – Eastern Europe, Central Asia, Asia, Caribbean and Latin/Central America

Poor performance of prevention and treatment cascades - with PWID>>SW>MSM

Different issues in the cascades by risk group

Pilots without scaling

**Unrelenting stigma and discrimination**  
**Investments have not achieved impact**

### Key gaps

Clinical and prevention cascade for key populations


Inconsistent political will to address all key populations with necessary prevention interventions

Impactful strategies to address stigma and discrimination



Concentrated epidemics

# New Infections in Russia vs Ukraine 2000-2017



# Lesson learned from Key Population epidemics

Progress is not possible  
without political will and peer  
provided prevention and  
treatment services

# Reducing Incidence

**PEPFAR**  
U.S. President's Emergency Plan for AIDS Relief



# How do we lower incidence?

- Treatment as prevention:  
aggressive scale-up of Test and Treat
  - Use better regimens: TLD
  - Ensure adherence and monitor VL for suppression
- VMMC
- Pre-Exposure Prophylaxis for those at highest risk
- Targeted prevention programming for most vulnerable - DREAMS



**PrEP:**  
*HIV PREVENTION  
WITH JUST  
1 PILL A DAY*



- Incidence monitoring using POC of recency assay to target prevention activities

# Reducing Mortality

**PEPFAR**  
U.S. President's Emergency Plan for AIDS Relief



# How do we lower mortality?

- Ensure early diagnosis and treatment
- Ensure treatment adherence and VL reduction
- Directly address the leading cause of death: TB
  - Early diagnosis and treatment of HIV and TB disease
  - TB Preventive Therapy
- Treat other causes of death for relevant populations: cervical cancer in women
- Monitor mortality and (re)direct resources as indicated




# **Better drugs, better adherence**

## **Comprehensive approach to TB prevention and treatment**


- TLD is better tolerated, with higher efficacy and lower incidence of adverse events
- Treatment literacy will be critical for drug introductions

# Rapid ART introduction is the single most impactful intervention to reduce overall mortality and risk of TB disease among PLHIV



# New PEPFAR/PRRR strategy would reduce incidence of cervical cancer in HIV+ women by ~95%


HIV-positive cervical cancer incidence rate per 100,000 women, by age



# New Indicators Driving PEPFAR Programming

- **TB\_PREV** is a mandatory indicator, will capture *completion* of TB preventive therapy
  - Accommodates different regimens
- **ART\_ML** will capture overall mortality and loss to follow up
  - Will allow us to identify which populations have higher mortality and require targeted interventions and understand why

# Leveraging 'U=U' to address self stigma and community stigma



# PEPFAR

U.S. President's Emergency Plan for AIDS Relief



## Thank You!

**15 YEARS OF SAVING LIVES THROUGH AMERICAN GENEROSITY AND PARTNERSHIPS**

**#PEPFAR15**